# Vicinitas Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vicinitas-therapeutics

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.vicinitastx.com
- Total disclosed funding: $65M
- Latest round: Series A (Apr 12, 2022)
- Investors on record: 6

## About

Based in California, US, and founded in 2022, Vicinitas Therapeutics operates as a biotechnology company that develops small-molecule drugs. The company was founded by Dan Nomura. In July 2022, Vicinitas Therapeutics raised USD 65 million in series A funding co-led by Andreessen Horowitz, Deerfield Management, Berkeley Catalyst Fund, and DROIA Ventures.

Vicinitas Therapeutics offers Deubiquitinase Targeting Chimera (DUBTAC), which is a targeted protein stabilization (TPS) platform that is focused on many diseases that are driven by proteins, which include cancer and monogenic diseases. The company's TPS platform provides development based on heterobifunctional small molecules, which contain an OTUB1 recruiter for the deubiquitinase and a ligand that targets proteins.

## Funding rounds

- Series A, Apr 12, 2022, $65M — GV, Andreessen Horowitz, Deerfield Management, Droia Ventures, Berkeley Catalyst Fund, Mark Foundation for Cancer Research

## Investors

- GV (https://capitalatlas.ai/funds/gv) — Series A
- Andreessen Horowitz (https://capitalatlas.ai/funds/andreessen-horowitz) — Series A
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series A
- Droia Ventures (https://capitalatlas.ai/funds/droia-ventures) — Series A
- Berkeley Catalyst Fund (https://capitalatlas.ai/funds/berkeley-catalyst-fund) — Series A
- Mark Foundation for Cancer Research — Series A